Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsBarbara K. Felber, George N. Pavlakis
Life of this patent
Estimating the term…
Abstract
The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence encoding an improved IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL-15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).
Claims27
-60. (canceled)
An expression vector comprising:
- an IL-15 nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide, wherein the IL-15 nucleic acid sequence has at least 85% sequence identity to nucleotides 145-489 SEQ ID NO:3;
- and
- an IL-15 receptor α (IL-15Rα) nucleic acid sequence encoding an IL-15Rα polypeptide;
- wherein the IL-15 nucleic acid sequence and the IL-15Rα nucleic acid sequence are each operably linked to a promoter.
A host cell comprising an IL-15 nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide, wherein the IL-15 nucleic acid sequence has at least 85% sequence identity to nucleotides 145-489 SEQ ID NO:3;
- and an IL-15 receptor α (IL-15Rα) nucleic acid sequence encoding an IL-15Rα polypeptide.
Dependencies are inferred from the claim text.